Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Calquence

- PMLiVE

AstraZeneca’s Imfinzi combination shows promise in phase 3 liver cancer study

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

EU flag

EC opens participation to new alliance addressing critical drug shortages

The Critical Medicines Alliance is expected to publish its first advice by autumn 2024

- PMLiVE

Roche’s subcutaneous Tecentriq granted EC approval for multiple cancer types

The formulation reduces treatment time by around 80% compared to intravenous infusion

- PMLiVE

Pfizer’s Talzenna combination receives EC approval for metastatic prostate cancer

Approximately 470,000 new cases of prostate cancer were reported in Europe in 2020

- PMLiVE

AstraZeneca/Sanofi’s RSV treatment shown to reduce hospitalisations in infants

Beyfortus showed an over 80% reduction in hospitalisations associated with the virus

EU flag

EC approves UCB’s Rystiggo to treat generalised myasthenia gravis

The autoimmune disease has a global prevalence of 100 to 350 cases per every one million people

- PMLiVE

AstraZeneca and Ionis’ Wainua granted FDA approval for rare disease ATTRv-PN

ATTRv-PN leads to peripheral nerve damage with motor disability within five years of diagnosis

- PMLiVE

AstraZeneca to acquire cell therapy specialist Gracell in deal worth up to $1.2bn

The transaction includes a clinical-stage candidate being evaluated as a treatment for multiple myeloma

- PMLiVE

AstraZeneca/Merck’s Lynparza recommended by NICE for advanced prostate cancer

The combination therapy has been recommended for patients regardless of biomarker status

EU flag

EC approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

- PMLiVE

Merck’s Keytruda approved by EC for two new gastrointestinal cancer indications

Both approvals follow recommendations from the European Medicines Agency’s human medicines committee

- PMLiVE

EC, HMA and EMA publish first version of Union list of critical medicines

The established list aims to prevent potential future shortages of critical medicines in the EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links